Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.